AAAAAA

   
Results: 1-9 |
Results: 9
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults
Authors: Cremieux, AC Katlama, C Gillotin, C Demarles, D Yuen, GJ Raffi, F
Citation: Ac. Cremieux et al., A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, PHARMACOTHE, 21(4), 2001, pp. 424-430
In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
Authors: Sadler, BM Gillotin, C Lou, Y Stein, DS
Citation: Bm. Sadler et al., In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor, ANTIM AG CH, 45(3), 2001, pp. 852-856
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
Authors: Sadler, BM Gillotin, C Lou, Y Eron, JJ Lang, W Haubrich, R Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
Authors: Sadler, BM Gillotin, C Lou, Y Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing, ANTIM AG CH, 45(1), 2001, pp. 30-37
The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome
Authors: Dhonneur, G Cerf, C Lagneau, F Mantz, J Gillotin, C Duvaldestin, P
Citation: G. Dhonneur et al., The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome, ANESTH ANAL, 93(2), 2001, pp. 400-404
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virustype 1 protease inhibitor, in subjects with normal or impaired hepatic function
Authors: Veronese, L Rautaureau, J Sadler, BM Gillotin, C Petite, JP Pillegand, B Delvaux, M Masliah, C Fosse, S Lou, Y Stein, DS
Citation: L. Veronese et al., Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virustype 1 protease inhibitor, in subjects with normal or impaired hepatic function, ANTIM AG CH, 44(4), 2000, pp. 821-826
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers
Authors: Brophy, DF Israel, DS Pastor, A Gillotin, C Chittick, GE Symonds, WT Lou, Y Sadler, BM Polk, RE
Citation: Df. Brophy et al., Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers, ANTIM AG CH, 44(4), 2000, pp. 978-984
Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food
Authors: Chittick, GE Gillotin, C McDowell, JA Lou, Y Edwards, KD Prince, WT Stein, DS
Citation: Ge. Chittick et al., Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food, PHARMACOTHE, 19(8), 1999, pp. 932-942
Lack of a pharmacokinetic interaction between atovaquone and proguanil
Authors: Gillotin, C Mamet, JP Veronese, L
Citation: C. Gillotin et al., Lack of a pharmacokinetic interaction between atovaquone and proguanil, EUR J CL PH, 55(4), 1999, pp. 311-315
Risultati: 1-9 |